Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study:
Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics
characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the
advanced malignant tumor subjects;
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Collaborators:
Beijing Cancer Hospital Second Affiliated Hospital of Soochow University